Yvonne Hui, who serves as Principal Accounting Officer at Phreesia, Inc. (NASDAQ: PHR), disclosed a sale of company shares in a recent SEC Form 4 filing. The transaction, dated April 17, 2026, shows Hui sold 1,327 shares of Phreesia common stock at $9.28 per share, for total proceeds of $12,314. After the sale, Hui directly holds 24,664 shares of the company.
The filing specifies the trade was executed pursuant to a pre-established Rule 10b5-1 trading plan, which Hui adopted on January 15, 2026. The existence of the 10b5-1 plan indicates the transaction followed the parameters set out in that automatic trading arrangement.
Phreesia's shares have been volatile in recent months. According to the data cited in the filing, the stock is down 59% over the past six months but gained 9.7% over the last week. An InvestingPro analysis included in the reporting indicates the shares may be undervalued at current levels and points readers to a Pro Research Report covering Phreesia and more than 1,400 other U.S. equities for additional context.
Separately, the company released fourth-quarter fiscal 2026 results showing revenue of $127.1 million, slightly above the consensus estimate of $126.6 million. Phreesia also reported adjusted EBITDA of $29.4 million, beating the Street's expectation of $28.1 million. Despite these modest outperformance metrics, management lowered fiscal 2027 revenue guidance by roughly 7%, attributing the revision to lower advertising spend commitments from pharmaceutical clients.
The guidance adjustment has prompted multiple analyst updates. Raymond James trimmed its price target to $16 while keeping an Outperform rating. BMO Capital reduced its target to $14 and maintained a Buy rating, and DA Davidson also set a $14 target with a Buy stance. Citizens adjusted its view by downgrading the stock to Market Perform from Market Outperform. In contrast, KeyBanc reaffirmed an Overweight rating and kept a $28 price target.
These developments combine insider activity, recent earnings outcomes, and analyst repositioning to create a mixed picture for investors monitoring Phreesia. The insider sale was carried out under a pre-arranged plan, the company posted slight beats for the quarter, and guidance was revised downward due to reduced pharmaceutical advertising commitments, with analysts responding through target and rating adjustments.